Nausea during pregnancy combated by UK drug Xonvea ®

Digital health information to be made available to NHS staff and patients

Alliance Pharma plc, has announced the launch of Xonvea® (doxylamine succinate 10mg/pyridoxine hydrochloride 10mg) in the UK. Xonvea is indicated for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management, and is now available in the UK for women with NVP where there is an unmet need.

NVP is one of the most common reasons for pregnant women to be admitted to hospital. In 2016‐ 2017, there were 33,071 hospital admissions for NVP in England, resulting in 36,171 bed days. A recent study has estimated that NVP could cost the NHS in the UK up to £62.3 million per year.

Xonvea versus placebo has demonstrated significant improvement in NVP symptoms. There was also a significant improvement in quality of life compared to placebo. Anti‐histamines are recommended by the Royal College of Obstetricians & Gynaecologists (RCOG) and the National Institute of Clinical Excellence (NICE) as first‐line pharmacotherapy for the treatment of NVP after non‐pharmacological options. However, none of the treatments currently prescribed to treat NVP are licensed for use in pregnant women.

Peter Butterfield, Alliance Pharma’s Chief Executive Officer, said; “We are delighted that Xonvea, a new licensed medicine for the treatment of NVP is being introduced into the UK, and will now be available to women across the country. We hope that Xonvea will enable many more women with NVP, whose symptoms persist despite conservative measures, to be effectively managed in a community setting.”

Professor Catherine Nelson‐Piercy, consultant obstetric physician added; “I am delighted that at last the UK has a licensed medication for the treatment of nausea and vomiting of pregnancy where conservative treatment has failed. This delayed release formulation of doxylamine and pyridoxine has been used in millions of pregnant women worldwide. Primary and secondary care doctors caring for pregnant women in the UK are now able to prescribe Xonvea, affording women in the UK a licensed option when it comes to managing this often debilitating condition. In women who do not respond completely to Xonvea, doctors can prescribe other anti‐sickness drugs recommended by National Clinical Guidelines”.


Looking for more articles like this? Read herePharma News

Related articles:

Natera’s new biomarker for adverse pregnancy outcomes

RCOG comments on 55% drop in teenage pregnancy rates

RCOG: Early diagnosis is key to reduce placenta complications


Find your dream role at PharmaJobs.co.uk